Merus N.V.

Subsidiary of Genmab (GMAB)

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Zenocutuzumab(Bizengri)
Approved
HER2; HER3 (blocks NRG1 binding to HER3)Multispecific antibody
Non-Small Cell Lung CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma
Cholangiocarcinoma
Phase 2
EGFR x c-METMultispecific antibody
Non-Small Cell Lung Cancer

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Zenocutuzumab · BizengriPhase 2Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Est. primary completion 2026-12-31 · NCT02912949 · CT.gov ↗
What to watch
2028 (2)
April 2028 (2)
PamvatamigPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2028-04 · NCT06885840 · CT.gov ↗
What to watch
PamvatamigPhase 1/2Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
Est. primary completion 2028-04-30 · NCT04930432 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
PamvatamigPhase 1/2Solid Advanced Tumor
Est. primary completion 2029-02-01 · NCT07448116 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 May 2026ApprovalZenocutuzumabFDA Boxed Warning on Bizengri (BLA761352)
US, FDA · FDA · Source ↗

Financial reports

Quarterly & interim (13)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$12M$80M$367M$96Mreport ↗
View 12 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q2$8.8M$94M$444M$158Mreport ↗
2025-Q1$26M$80M$198M$96Mreport ↗
2024-Q3$12M$63M$434M$100Mreport ↗
2024-Q2$7.3M$49M$630M$50Mreport ↗
2024-Q1$7.9M$39M$179M$34Mreport ↗
2023-Q3$11M$37M$243M$23Mreport ↗
2023-Q2$10M$28M$102M$32Mreport ↗
2023-Q1$14M$35M$103M$40Mreport ↗
2022-Q3$6.6M$42M$192M$25Mreport ↗
2022-Q2$13M$31M$215M$5.7Mreport ↗
2022-Q1$12M$27M$195M$19Mreport ↗
2021-Q3$14M$26M$159M$15Mreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$36M$225M$293M$215Mreport ↗

Merus N.V. reported revenue of $36.133M, down 17.8% YoY, R&D spend of $225.368M, up 60.2% YoY, cash and equivalents of $293.294M, and a quarterly net burn of $215.326M for fiscal year 2024.

Figures only: this period's report disclosed no narrative text

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$44M$141M$204M$155Mreport ↗
2022-FY$42M$149M$148M$131Mreport ↗
2021-FY$49M$98M$242M$17Mreport ↗